Vyvgart Hytrulo, China and Zai Lab
(ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental ...
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | ...
Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...
The firm sees upside potential for the shares driven by Vyvgart sales and key trial outcomes and Phase 3 starts expected over the next 12 months. Steady quarter-over-quarter growth in the ...
ARGEN is a patented light scattering instrument that addresses key research and development issues in the biopharmaceutical industry by providing real-time stability monitoring, manufacturing ...
X, the social network formerly known as Twitter, would really like to be the app you use for everything – and that everything includes voice and video calls. Since yesterday those features have ...
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback